← All Beigene, LTD filings

Beigene, LTD DEF 14A proxy statements

Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.

BGNE
Beigene, LTD
DEFA14A: BeiGene to Hold 2025 Annual General Meeting, Seeking Shareholder Approval on Key Proposals
BeiGene's 2025 Annual General Meeting will address director re-elections, auditor ratification, share issuance and repurchase mandates, and other corporate matters.
BGNE
Beigene, LTD
DEF: BeiGene Eyes Global Expansion with Name Change, Redomiciliation, and Promising Pipeline
BeiGene plans to change its name to BeOne Medicines Ltd. and redomicile to Switzerland in the first half of 2025, reflecting its growing global presence and commitment to eliminating cancer.
BGNE
Beigene, LTD
DEFA14A: BeiGene to Hold Extraordinary General Meeting to Approve Swiss Continuation
BeiGene is holding an Extraordinary General Meeting (EGM) on April 28, 2025, to seek shareholder approval for its de-registration in the Cayman Islands and continuation in Switzerland.
BGNE
Beigene, LTD
DEF 14A: BeiGene Seeks Shareholder Approval for Director Re-elections, Equity Grants, and Amended Incentive Plans
BeiGene's proxy statement outlines proposals for the 2024 annual general meeting, including director re-elections, auditor ratification, share issuance and repurchase mandates, and amendments to equity incentive plans.